Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F19%3A73596374" target="_blank" >RIV/61989592:15110/19:73596374 - isvavai.cz</a>
Result on the web
<a href="https://jitc.biomedcentral.com/articles/10.1186/s40425-019-0508-1" target="_blank" >https://jitc.biomedcentral.com/articles/10.1186/s40425-019-0508-1</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1186/s40425-019-0508-1" target="_blank" >10.1186/s40425-019-0508-1</a>

Result language
angličtina
Original language name
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial
Original language description
BackgroundWe evaluated the antitumor activity and safety of avelumab, a human anti-PD-L1 IgG1 antibody, as first-line switch-maintenance (1L-mn) or second-line (2L) treatment in patients with advanced gastric/gastroesophageal cancer (GC/GEJC) previously treated with chemotherapy.MethodsIn a phase 1b expansion cohort, patients without (1L-mn) or with (2L) disease progression following first-line chemotherapy for advanced GC/GEJC received avelumab 10mg/kg intravenously every 2weeks. Endpoints included best overall response, progression-free survival (PFS), overall survival (OS), and safety.ResultsOverall, 150 patients were enrolled (1L-mn, n=90; 2L, n=60) and median follow-up in the 1L-mn and 2L subgroups was 36.0 and 33.7months, respectively. The confirmed objective response rate was 6.7% in both subgroups (95% CI, 2.5-13.9% and 1.8-16.2%, respectively), including complete responses in 2.2% of the 1L-mn subgroup (n=2). In the 1L-mn and 2L subgroups, median duration of response was 21.4months (95% CI, 4.0-not estimable) and 3.5months (95% CI, 2.8-8.3) and disease control rates were 56.7 and 28.3%, respectively.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)